Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.

@article{Dransfield2014EfficacyAS,
  title={Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.},
  author={Mark Thomas Dransfield and Gregory J. Feldman and Phillip E. Korenblat and Craig Laforce and Nicholas W Locantore and Massimo Pistolesi and Michael L. Watkins and Courtney C Crim and Fernando J Martinez},
  journal={Respiratory medicine},
  year={2014},
  volume={108 8},
  pages={1171-9}
}
BACKGROUND Fluticasone furoate/vilanterol (FF/VI) is an inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA), recently approved as once-daily maintenance therapy for COPD. We compared the lung function effects of FF/VI with those of twice-daily fluticasone propionate/salmeterol (FP/SAL). METHODS Three 12 week studies comparing FF/VI and FP/SAL were conducted. Patients aged ≥40 years with moderate-to-very severe COPD were randomized to receive double-blind, double-dummy FF/VI 100/25 mcg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…